MedWatch

Denmark-founded Oscine Therapeutics sold in possible billion-kroner trade

The biotech firm Oscine Therapeutics, which develops cell therapies for nervous-system diseases, has been sold to US Sana Biotechnology in a trade amounting to nearly DKK 1.3bn, according to MedWatch's information. "You don't find these things lying around, so of course I'm incredibly proud," says Co-Founder Christina Trojel-Hansen.

Christina Trojel-Hansen just sold her biotech company Oscine Therapeutics to a firm founded by the people behind Juno Therapeutics. | Foto: Christina Trojel-Hansen, adm. direktør i Oscine

A biotech fairy tale has ended happily for Christina Trojel-Hansen. In 2017, she founded and took up the role of CEO at the biotech Oscine Therapeutics, which develops cell therapies for diseases in the central nervous system.

On Friday, the 38-year-old researcher and businesswoman closed a deal which, according to MedWatch's information, will ultimately surpass one billion kroner with some of the greatest names in the cell therapy area in the biotech industry.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Biontech-direktører: Derfor måtte Afrika vente på coronavacciner

Tyske Biontech vil bruge de mange corona-milliarder på at hjælpe lande i Afrika med at komme både coronavirus, malaria og turberkulose til livs, men alligevel stod kontinentet langt nede i køen, da de første coronavacciner skulle distribueres. MedWatch har spurgt hvorfor.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier